Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 5/20 | 0.63 |
| ▸ | DRD3 | P35462 | 5/20 | 0.58 |
| ▸ | DRD1 | P21728 | 2/20 | 0.58 |
| ▸ | HTR1A | P08908 | 2/20 | 0.54 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 3/20 | 0.53 |
| ▸ | DRD5 | P21918 | 3/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1254641 | 0.98 | HTR7 (0.66) | HTR7DRD3DRD1HTR1AHTR2A | |
| SCHEMBL1254429 | 0.94 | HTR7 (0.60) | HTR7DRD3DRD1HTR1ADRD2 | |
| SCHEMBL2195868 | 0.89 | HTR7 (0.47) | HTR7DRD3DRD1HTR1AHTR2A | |
| SCHEMBL1254385 | 0.87 | KCNH2 (0.57) | HTR7DRD3DRD1HTR1AHTR2A | |
| SCHEMBL2191733 | 0.87 | HTR7 (0.50) | HTR7DRD3DRD1HTR1AHTR2A | |
| SCHEMBL4050945 | 0.86 | HTR7 (0.48) | HTR7DRD3DRD1HTR1AHTR2A | |
| SCHEMBL1255686 | 0.85 | KCNH2 (0.60) | HTR7DRD3HTR1AHTR2ADRD2 | |
| SCHEMBL2191705 | 0.84 | HTR7 (0.44) | HTR7DRD3DRD1HTR1AHTR2A | |
| SCHEMBL2194425 | 0.83 | HTR7 (0.43) | HTR7DRD3DRD1HTR1AHTR2A | |
| SCHEMBL2194603 | 0.82 | DRD2 (0.46) | HTR7DRD3DRD1HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | claimed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | claimed |
| EP-2285373-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2011-02-23 | — | — | EP | claimed |
| EP-2219648-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | Cenomed Biosciences, LLC (US) | 2010-08-25 | — | — | EP | claimed |
| WO-2010036395-A2 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2010-04-01 | — | — | WO | claimed |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-10-22 | — | — | US | claimed |
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2009-06-18 | — | — | US | claimed |
| WO-2009062134-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | CENOMED BIOSCIENCES, LLC (US) | 2009-05-14 | — | — | WO | claimed |
| US-20050107439-A1 | Composition and method for treating emesis | HELTON DAVID R (US) | 2005-05-19 | — | — | US | claimed |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | HELTON DAVID REED (US) | 2015-02-19 | — | — | US | disclosed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | ABRAXIS BIOSCIENCE, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20050107439-A1 | Composition and method for treating emesis | HELTON DAVID R (US) | 2005-05-19 | — | — | US | disclosed |
| US-6770638-B2 | PSYCHOLOGICAL DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | SPECTRUM PHARMACEUTICALS, INC. | 2004-08-03 | — | — | US | disclosed |
| EP-1412028-A1 | TETRAHYDROINDOLONE AND PURINE DERIVATIVES LINKED TO ARYLPIPERAZINES | Neotherapeutics, Inc. (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030114463-A1 | Tetrahydroindolone and purine derivatives linked to arylpiperazines | SPECTRUM PHARMACEUTICALS, INC. | 2003-06-19 | — | — | US | disclosed |
| WO-2003011396-A1 | TETRAHYDROINDOLONE AND PURINE DERIVATIVES LINKED TO ARYLPIPERAZINES | NEOTHERAPEUTICS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
| WO-2003011396-A1 | TETRAHYDROINDOLONE AND PURINE DERIVATIVES LINKED TO ARYLPIPERAZINES | NEOTHERAPEUTICS, INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156609-A1 | TREATMENT OF POST-TRAUMATIC STRESS DISORDER WITH TETRAHYDROINDOLONE ARYLPIPERZAINE COMPOUNDS | HTR5A, HTR2C, HTR3B | HTR7 20/4885DRD3 34/4885DRD1 33/4885 |
| US-20110172242-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR7 199/4885DRD3 1448/4885DRD1 2483/4885 |
| US-20150051219-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR7 199/4885DRD3 1448/4885DRD1 2483/4885 |
| US-20030114463-A1 | Tetrahydroindolone and purine derivatives linked to arylpiperazines | HTR5A, GABRA5, HTR2C | HTR7 7/4885DRD3 65/4885DRD1 54/4885 |
| US-20050107439-A1 | Composition and method for treating emesis | VIP, HNMT, FABP2 | HTR7 119/4885DRD3 3181/4885DRD1 3723/4885 |
| US-20090264443-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS | DDT, CYP4X1, AHR | HTR7 199/4885DRD3 1448/4885DRD1 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.